South Africa in Talks with Gilead for HIV Therapy Production Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy GILD?
Source: seekingalpha
- HIV Treatment Advancement: South Africa is in discussions with Gilead Sciences (GILD) to establish a production agreement for lenacapavir, a new HIV therapy approved by the FDA in July 2025, addressing the needs of over 8 million HIV-positive individuals in the country.
- Local Production Initiative: The government has called for expressions of interest from South African pharmaceutical manufacturers capable of producing the antiviral therapy, aiming to enhance the predictability and sustainability of drug supply through local production.
- Global Supply Diversification: Gilead granted six voluntary licenses to drugmakers in India, Egypt, and Pakistan in 2024, and a seventh license for a South African manufacturer would further diversify the global supply chain and strengthen production capacity in regions with high HIV burdens.
- Accelerating Drug Accessibility: Unitaid noted that producing lenacapavir closer to where it is most needed could accelerate the pathway from innovation to access, ensuring a more stable supply and helping South Africa effectively combat the HIV epidemic.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 145.140
Low
105.00
Averages
137.88
High
154.00
Current: 145.140
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of QQQM ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQM ETF's 52-week low is $165.72 per share, with a high of $262.2342, while the last trade was at $248.42, indicating stability near the high point which may attract investors looking for pullback opportunities.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, thus impacting the underlying holdings and reflecting market supply and demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market sentiment.
See More
Stock Futures Plunge as Jefferies Faces Lawsuit Over $126.4M Claim
- Jefferies Lawsuit Crisis: Jefferies Financial faces a lawsuit from Western Alliance Bancorporation for allegedly failing to pay $126.4 million under a forbearance agreement, resulting in a 2% drop in premarket trading, which could undermine its market credibility and future financing capabilities.
- Trade Desk Downgrade: Wedbush downgraded Trade Desk's investment rating from 'neutral' to 'underperform', citing an overestimation of the positive impact from the rumored OpenAI deal, leading to a 1.98% decline in premarket shares, potentially affecting its future investment appeal.
- Nike Restructuring Costs: Nike expects to incur approximately $300 million in pretax charges related to employee severance over the next nine months, with a 0.36% drop in premarket trading, indicating short-term financial pressure as the company seeks to enhance operational efficiency and profitability.
- Gilead Negotiations with South Africa: Gilead Sciences saw a 1% decline in premarket trading amid discussions with South Africa regarding local production of its HIV therapy lenacapavir, a move that could impact Gilead's market share and supply chain in the region.
See More
Three Cash Flow Generators Offer Stability in Volatile Markets
Importance of Cash Flow: Cash flow is crucial for companies to meet short-term obligations and plan for long-term stability, impacting everything from expansion plans to shareholder returns.
Gilead Sciences' Performance: Gilead Sciences is highlighted as a leading biopharma firm with strong cash flow generation, returning a significant portion of its free cash flow to shareholders, and maintaining growth through new product rollouts.
AbbVie’s Dividend Strategy: AbbVie has a solid cash flow yield and a history of increasing dividend distributions, making it an attractive option for investors despite concerns about its ability to sustain high payout ratios.
Visa's Resilience: Visa demonstrates strong cash generation capabilities, allowing it to maintain and grow dividends, even amid economic challenges, positioning it as a stable investment choice for many analysts.
See More
South Africa in Talks with Gilead for HIV Therapy Production Agreement
- HIV Treatment Advancement: South Africa is in discussions with Gilead Sciences (GILD) to establish a production agreement for lenacapavir, a new HIV therapy approved by the FDA in July 2025, addressing the needs of over 8 million HIV-positive individuals in the country.
- Local Production Initiative: The government has called for expressions of interest from South African pharmaceutical manufacturers capable of producing the antiviral therapy, aiming to enhance the predictability and sustainability of drug supply through local production.
- Global Supply Diversification: Gilead granted six voluntary licenses to drugmakers in India, Egypt, and Pakistan in 2024, and a seventh license for a South African manufacturer would further diversify the global supply chain and strengthen production capacity in regions with high HIV burdens.
- Accelerating Drug Accessibility: Unitaid noted that producing lenacapavir closer to where it is most needed could accelerate the pathway from innovation to access, ensuring a more stable supply and helping South Africa effectively combat the HIV epidemic.
See More
Gilead Executive Anticipates Anti-Cel Launch by Year-End at TD Cowen Conference
- Launch Announcement: The Sanito-Cel is expected to launch by the end of this year, as stated by Gilead executives.
- Event Context: This announcement was made during the TD Cowen conference, highlighting the company's strategic plans.
See More
Gilead Executive Highlights Potential $20 Billion Market for Anti-Cel in First-Line Multiple Myeloma Treatment at TD Cowen Conference
Potential Financial Impact: Sanito-Cel could potentially add up to $20 billion in value through its multiple myeloma treatment options.
Focus on First-Line Treatment: The emphasis is on the use of Sanito-Cel in first-line treatment settings, highlighting its significance in addressing this type of cancer.
See More
Analysis of QQQM ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQM ETF's 52-week low is $165.72 per share, with a high of $262.2342, while the last trade was at $248.42, indicating stability near the high point which may attract investors looking for pullback opportunities.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, thus impacting the underlying holdings and reflecting market supply and demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market sentiment.
See More
Stock Futures Plunge as Jefferies Faces Lawsuit Over $126.4M Claim
- Jefferies Lawsuit Crisis: Jefferies Financial faces a lawsuit from Western Alliance Bancorporation for allegedly failing to pay $126.4 million under a forbearance agreement, resulting in a 2% drop in premarket trading, which could undermine its market credibility and future financing capabilities.
- Trade Desk Downgrade: Wedbush downgraded Trade Desk's investment rating from 'neutral' to 'underperform', citing an overestimation of the positive impact from the rumored OpenAI deal, leading to a 1.98% decline in premarket shares, potentially affecting its future investment appeal.
- Nike Restructuring Costs: Nike expects to incur approximately $300 million in pretax charges related to employee severance over the next nine months, with a 0.36% drop in premarket trading, indicating short-term financial pressure as the company seeks to enhance operational efficiency and profitability.
- Gilead Negotiations with South Africa: Gilead Sciences saw a 1% decline in premarket trading amid discussions with South Africa regarding local production of its HIV therapy lenacapavir, a move that could impact Gilead's market share and supply chain in the region.
See More
Three Cash Flow Generators Offer Stability in Volatile Markets
Importance of Cash Flow: Cash flow is crucial for companies to meet short-term obligations and plan for long-term stability, impacting everything from expansion plans to shareholder returns.
Gilead Sciences' Performance: Gilead Sciences is highlighted as a leading biopharma firm with strong cash flow generation, returning a significant portion of its free cash flow to shareholders, and maintaining growth through new product rollouts.
AbbVie’s Dividend Strategy: AbbVie has a solid cash flow yield and a history of increasing dividend distributions, making it an attractive option for investors despite concerns about its ability to sustain high payout ratios.
Visa's Resilience: Visa demonstrates strong cash generation capabilities, allowing it to maintain and grow dividends, even amid economic challenges, positioning it as a stable investment choice for many analysts.
See More
South Africa in Talks with Gilead for HIV Therapy Production Agreement
- HIV Treatment Advancement: South Africa is in discussions with Gilead Sciences (GILD) to establish a production agreement for lenacapavir, a new HIV therapy approved by the FDA in July 2025, addressing the needs of over 8 million HIV-positive individuals in the country.
- Local Production Initiative: The government has called for expressions of interest from South African pharmaceutical manufacturers capable of producing the antiviral therapy, aiming to enhance the predictability and sustainability of drug supply through local production.
- Global Supply Diversification: Gilead granted six voluntary licenses to drugmakers in India, Egypt, and Pakistan in 2024, and a seventh license for a South African manufacturer would further diversify the global supply chain and strengthen production capacity in regions with high HIV burdens.
- Accelerating Drug Accessibility: Unitaid noted that producing lenacapavir closer to where it is most needed could accelerate the pathway from innovation to access, ensuring a more stable supply and helping South Africa effectively combat the HIV epidemic.
See More
Gilead Executive Anticipates Anti-Cel Launch by Year-End at TD Cowen Conference
- Launch Announcement: The Sanito-Cel is expected to launch by the end of this year, as stated by Gilead executives.
- Event Context: This announcement was made during the TD Cowen conference, highlighting the company's strategic plans.
See More
Gilead Executive Highlights Potential $20 Billion Market for Anti-Cel in First-Line Multiple Myeloma Treatment at TD Cowen Conference
Potential Financial Impact: Sanito-Cel could potentially add up to $20 billion in value through its multiple myeloma treatment options.
Focus on First-Line Treatment: The emphasis is on the use of Sanito-Cel in first-line treatment settings, highlighting its significance in addressing this type of cancer.
See More
